Dr. Han Liu is the Cuiying Postdoctoral Fellow at the College of Veterinary Medicine, Lanzhou University. She received her B.S. in Pharmacy and M.S. in Pharmacology from Guangzhou University of Chinese Medicine, followed by a Ph.D. in Medicinal Chemistry from Sun Yat-sen University.
Her research focuses on the discovery and development of peptide therapeutics and antibody-based drugs, with particular interests in targeted protein degradation, lysosomal targeting technologies, fibrosis, inflammation, and autoimmune diseases. She has led multiple competitive research projects, including the China Postdoctoral Science Foundation, provincial natural science grants, university research programs, and National Key Laboratory open projects, while also participating in several national key research initiatives.
Dr. Liu has published SCI-indexed papers in leading international journals, including Acta Pharmaceutica Sinica B, Journal of Medicinal Chemistry, and Phytomedicine, serving as first author or corresponding author on multiple publications. Her work has been recognized with the Best Abstract Award from the European Crohn's and Colitis Organisation (ECCO). She has also contributed to the preclinical development of two Class 1 innovative drug candidates that have advanced into Phase I and Phase II clinical trials.
Her current research aims to develop innovative peptide- and antibody-based therapeutic strategies for the treatment of fibrosis, inflammatory disorders, and autoimmune diseases.
Research Grants
As Principal Investigator
China Postdoctoral Science Foundation
Natural Science Foundation of Gansu Province
Fundamental Research Funds for the Central Universities
National Key Laboratory Open Research Fund
Shenzhen Kunpeng Young Investigator Program
Industry-sponsored research projects
As Key Participant
National Key R&D Program of China
National Major Scientific and Technological Project for Chronic Diseases
Gansu Provincial Major Science and Technology Program
Guangzhou Nansha District Key Science and Technology Program
1.Wei X, Li H*, Cao J, Luo D, Qi L, Tang Q, Wu M, Qiu C, Shi Z, Jiang X*, Liu H*. Structure-Based Development of a Novel Macrocyclic Peptide to Disrupt the Lumican-Collagen I Interaction in Liver Fibrosis. J Med Chem. 2025 Nov 28. doi:10.1021/acs.jmedchem.5c02705.
2.Shi Z, Liu X, Wu S, Song N, Tang Q, Li H, Luo S, Chan A, Cai X, Liu H*, Jiang X*. Discovery of Novel Peptide Antagonists Targeting GPR55 for Liver Inflammation and Fibrosis. J Med Chem. 2024 Jul 25;67(14):12085-12098. doi: 10.1021/acs.jmedchem.4c00834.
3.Liu H1, Hong Y1, Chen H1, Wang X, Dong J, Li X, Shi Z, Wang J, Zhou L, Zeng Q, Tang Q, Liu Q, Rieder F, Chen B, Chen M, Zhang Y, Mao R, Jiang X*. Dual Activation of GCGR/GLP1R Signaling Ameliorates Intestinal Fibrosis via Metabolic Regulation of Histone H3K9 Lactylation in Epithelial Cells. Acta Pharm Sin B. 2024.
4.Liu H1, Hong Y, Wang X, Dong J, Li X, Shi Z, Wang J, Zhou L, Rieder F, Chen B, Chen M, Zhang Y, Mao R, Jiang X*. 173 Dual Activation of GCGR/GLP1R Signaling Ameliorates Intestinal Fibrosis via Metabolic Regulation of Histone H3K9 Lactylation in Epithelial Cells. Gastroenterology. Volume 166, Issue 5, Supplement, 18-21 May 2024, Pages S-39-S-40doi.org/10.1016/S0016-5085(24)00583-3.
5.Liu H1, Hong Y, Wang X, Dong J, Li X, Shi Z, Wang J, Zhou L, Rieder F, Chen B, Chen M, Zhang Y, Mao R, Jiang X*. OP25 Dual Activation of GCGR/GLP1R Signaling Ameliorates Intestinal Fibrosis via Metabolic Regulation of Histone H3K9 Lactylation in Epithelial Cells. J Crohns Colitis. Volume 18, Issue Supplement_1, January 2024, Pages i44-i46, 10.1093/ecco-jcc/jjad212.0025.
6.Zhao Q1, Dong J1, Liu H1, Chen H, Yu H, Ye S, Yu S, Li Y, Qiu L, Song N, Xu H, Liu Q, Luo Z, Li Y, Wang R, Chen G, Jiang X*. Design and Discovery of a Highly Potent Ultralong-acting GLP-1 and Glucagon Co-agonist for Attenuating Renal Fibrosis. Acta Pharm Sin B. 2024 Mar;14(3):1283-1301. doi: 10.1016/j.apsb.2023.11.020.
7.Liu H, Lu Z, Lin B, Zhan JY, Gui S, Chen W, Tang P, Li P, Yang W, Lin B*. Inferior Vena Cava Stenosis-induced Deep Vein Thrombosis is Influenced by Multiple Factors in Rats. Biomed Pharmacother. 2020 Aug;128:110270. doi: 10.1016/j.biopha.2020.110270.
8.Liu H, Li P, Lin J, Chen W, Guo H, Lin J, Liu J, Lu Z, Yao X, Chen Y, Lin B*. Danhong Huayu Koufuye Prevents Venous Thrombosis through Antiinflammation via Sirtuin 1/NF-κB Signaling Pathway. J Ethnopharmacol. 2019 Sep 15;241:111975. doi: 10.1016/j.jep.2019.111975.
9.Tang P1, Liu H1*, Lin B, Yang W, Chen W, Lu Z, Li P, Gui S, Zhan Y, Lin B*. Spatholobi Caulis Dispensing Granule Reduces Deep Vein Thrombus Burden through Antiinflammation via SIRT1 and Nrf2. Phytomedicine. 2020 Oct;77:153285. doi: 10.1016/j.phymed.2020.153285.
10.Yao X1, Liu H1, Li P, Chen W, Guan S, Chen Y, Wu Y, Lin B*. Aqueous Extract of Whitmania Pigra Whitman Alleviates Thrombus Burden via Sirtuin 1/NF-κB Pathway. J Surg Res. 2020 Jan;245:441-452. doi: 10.1016/j.jss.2019.07.094.
11.Wang Y, Xue F, Cheng W, Zhao Q, Song N, Shi Z, Liu H, Li Y, Tang Q, Liu Q, Wang Y, Zhang F, Jiang X*. Design and Synthesis of Novel Ultralong-acting Peptides as EDP-EBP Interaction Inhibitors for Pulmonary Fibrosis Treatment. J Med Chem. 2024 Apr 25;67(8):6624-6637. doi: 10.1021/acs.jmedchem.4c00067.
12.Dong J, Xiao J, Li J, Yu H, Zhao Q, Tang Q, Chen H, Liu H, Wu K, Lei J, Wang R, Jiang X*. Discovery and Design of Novel Cyclic Peptides as Specific Inhibitors Targeting CCN2 and Disrupting CCN2/EGFR Interaction for Kidney Fibrosis Treatment. J Med Chem. 2023 Jun 22;66(12):8251-8266. doi: 10.1021/acs.jmedchem.3c00594.
13.Yao X, Chen W, Liu J, Liu H, Zhan JY, Guan S, Lu Z, Tang P, Li P, Lin B. Deep Vein Thrombosis is Modulated by Inflammation Regulated via Sirtuin 1/NF-κB Signalling Pathway in a Rat Model. Thromb Haemost. 2019 Mar;119(3):421-430. doi: 10.1055/s-0038-1676987.
14.刘涵, 肖璨, 董嘉乐, 桂甜, 陈辉, 祁亮, 蒋先兴; 一种用于溶酶体运输的嵌合多肽分子及其应用, 2025-12-09, 中国, 2025120901908170 （专利）
15.蒋先兴, 刘涵, 李浩男, 邱创楠, 洪玉洁, 蔚金凤, 罗戴民, 药物辅助功能化多肽靶向细胞溶酶体的应用, 2025-12-04, 中国, 2025118181442 （专利）
16.蒋先兴; 洪玉洁; 刘涵; 一种多肽化合物及其在骨关节炎中的应用, 2024-3-25, 中国,2024103409292 （专利）
17.黄民; 刘涵; 王翔桂; 蒋先兴; 一种用于 NPR-B 靶向的超长效多肽及其在骨骼系统病症中的应用, 2024-12-2, 中国, ZL2024117476220 （专利）
